Study of insulin resistance in relation to serum IGF-I levels in subjects with different degrees of glucose tolerance

Introduction
Insulin resistance is a chronic metabolic syndrome characterized by a cluster of abnormalities including altered glucose tolerance, visceral adiposity, hypertension, low HDL cholesterol and high triglyceride levels. It is linked with so many cardiovascular diseases. [1] [2] There is an increasing evidence in the last few years suggesting that IGF-I may have a role in both glucose homeostasis and atherosclerotic cardiovascular disease. Animals with absence of liver speciÞ c IGF-I gene are characterized by hyperinsulinemia and skeletal muscle insulin resistance. [34] These animals when treated with recombinant IGF-I showed a reduction in insulin levels and an increase in insulin sensitivity. [3] Clinical studies performed in patients with extreme insulin resistance and in patients with both types of diabetes have shown that recombinant IGF-I administration significantly lowered blood glucose and increased insulin sensitivity. [5] [6] [7] [8] A recent study concluded that low concentrations of IGF-I in the blood circulation was increasingly associated with increased risk of developing type-2 diabetes. [9] In nondiabetic subjects, the low levels of IGF-I in circulation have been associated with angiographically reported coronary artery diseases. [10, 11] In patients with effort angina pectoris and angiographically normal epicardial coronary arteries (cardiac syndrome-X), low levels of IGF-I have been observed. [12] Individuals with low levels of IGF-I have increased risk of developing ischemic heart disease compared to individuals with normal levels of IGF-I. [13] Nondiabetic patients succumbing to an acute myocardial infarction had signiÞ cantly lower IGF-I levels than survivors. [14] In view of these Þ ndings, a close link between metabolic syndrome-X and insulin resistance, diabetes, and atherosclerotic coronary artery diseases might be attributed to the low levels of circulating IGF-I, which in turn affects insulin sensitivity. In the present study, we have evaluated the correlations between IGF-I concentrations and insulin sensitivity in both fasting and post-lunch serum samples using anthropometric and biochemical variables in subjects with different degrees of glucose tolerance.
Materials and Methods
The study included 12 nondiabetic subjects, 09 subjects with impaired glucose tolerance (IGT), and 18 patients with newly diagnosed type-2 diabetes. [15]
Ethics
The study was approved by Institutional Ethics Committee (Kakatiya Medical College, Warangal) and informed consent was obtained from each subject according to the principles of the declaration of Helsinki.
Biochemical assays
Fasting and post-lunch blood glucose, total and HDL cholesterol, and triglycerides were measured by enzymatic methods (Excel Diagnostics Private Limited, Hyderabad, India). Fasting and post-lunch serum insulin concentrations were determined by enzymelinked immunosorbent assay (ELISA) (Mercodia AB., Sweden). Fasting and post-lunch serum C-peptide concentrations were determined by ELISA (Biomerica Inc., USA). Fasting and post-lunch serum IGF-I concentrations were determined by ELISA (Mediagnost., Germany). Fasting and post-lunch serum VLDL and LDL cholesterol concentrations were determined by using the formula: VLDL cholesterol = triglycerides/5; and LDL cholesterol = total cholesterol -(HDL + VLDL cholesterol). [16] Insulin resistance was assessed by using the previously validated homeostasis model assessment for insulin resistance, calculated from the fasting insulin and glucose concentrations according to the formula: HOMA-IR = [(insulin X glucose)/22.5]. [17] Similarly, insulin sensitivity was assessed by using the previously validated homeostasis model assessment for insulin sensitivity, calculated from the fasting insulin and glucose concentrations according to the formula: HOMA-S = 1/ [(insulin X glucose) X 22.5]. [18] Statistical analysis All variables are expressed as mean ± SD. Group differences of continuous variables were compared using ANOVA followed by Newman Keuls test. Relationships between variables were determined by Pearson's correlation coefÞ cient. For all analyses, a P value <0.05 was considered to be statistically signiÞ cant. All analyses were performed using GraphPad Prism 4 Demo software.
Results
Anthropometric and biochemical characteristics of the study subjects are shown in Table 1 . Subjects with IGT and newly diagnosed type-2 diabetes were similar in age and had signiÞ cantly higher fasting and post-lunch blood glucose (P < 0.0001, P < 0.0001, respectively), and not signiÞ cantly higher fasting and post-lunch serum insulin, C-peptide, abnormal lipid proÞ le, and HOMA-IR levels compared with nondiabetic subjects. HDL cholesterol was not signiÞ cantly lower in subjects with IGT and diabetes compared with nondiabetic subjects. Interestingly, HOMA-S was not significantly lower in subjects with IGT and type-2 diabetes (P < 0.323). Fasting and postlunch serum IGF-I concentrations were signiÞ cantly lower in subjects with IGT as well as type-2 diabetes (P < 0.0001, P < 0.007, respectively).
Univariate correlations between both serum IGF-I concentrations and established components of the insulin resistance syndrome were assessed for the study subjects [ Table 2a , 2b, and 2c]. In all the subjects fasting and post-lunch serum IGF-I concentrations were negatively correlated with age, blood glucose, insulin, C-peptide, triglycerides, and total lipid proÞ le with an exception of HDL cholesterol and insulin resistance expressed as HOMA-IR. Fasting serum IGF-I concentrations were positively correlated with HDL cholesterol and insulin sensitivity (HOMA-S). Post-lunch serum IGF-I concentrations were positively correlated with LDL cholesterol in addition to HDL cholesterol. Correlations for HOMA-S with these metabolic variables were of a similar degree and in the same direction as that serum IGF-I concentrations. HOMA-S was negatively correlated with age, glucose, insulin, C-peptide, triglycerides, total cholesterol, and HOMA-IR. In contrast, it was positively correlated with HDL cholesterol and serum IGF-I.
However, the correlations between fasting serum IGF-I concentrations and established components of the insulin resistance syndrome including age and HDL cholesterol were significant in nondiabetic subjects, but not in IGT and newly detected type-II diabetic patients; and postlunch serum IGF-I did not show signiÞ cant correlation with age and HDL cholesterol. The correlations between fasting and postlunch serum IGF-I concentrations and established components of the insulin resistance syndrome including blood glucose, insulin, C-peptide, triglycerides, VLDL cholesterol, HOMA-IR, and HOMA-S were not significant in all subjects. The correlations between fasting serum IGF-I concentrations and total and LDL cholesterol were signiÞ cant in nondiabetic subjects and patients with newly detected type-2 diabetes, but not in IGT subjects and all the groups of subjects of post-lunch serum samples. The correlations between serum insulin sensitivity calculated from HOMA-S and serum insulin resistance estimated from HOMA-IR were statistically signiÞ cant in all subjects, while serum blood glucose, C-peptide, triglycerides, total lipid proÞ le, and IGF-I were not. The correlations of serum IGF-I and HOMA-S with all established components of insulin resistance syndrome are shown in the Table 2 .
Discussion
Serum IGF-I levels were positively correlated with insulin sensitivity and HDL cholesterol and negatively correlated with all components of insulin resistance syndrome. These relations of HOMA-S were similar in degree and directions to those observed with serum IGF-I levels. Furthermore, low levels of serum IGF-I were signiÞ cantly related with the metabolic syndrome according to the World Health Organization. [19] However, our Þ ndings are consistent with the animal studies demonstrating low insulin sensitivity in mice with liver speciÞ c deletion of the IGF-I gene that is reversed by treatment with recombinant human IGF-I. [3, 4] Raised blood pressure and slightly enhanced plasma together, it was suggested that GH hypersecretion may be a major determinant of insulin resistance in subjects with low-plasma-IGF-I concentrations.
In conclusion, the present study indicates that serum IGF-I concentrations, particularly low levels, may be a useful marker for identifying subjects at risk of developing type-2 diabetes mellitus and possible cardiovascular complications. Especially, post-lunch serum IGF-I levels may be important in identifying the onset of type-2 diabetes mellitus. The difference between fasting IGF-I and post-lunch IGF-I concentrations in IGT and type-2 diabetes mellitus are directly proportionate, probably indicating nonutilization of IGF-I in post-lunch state. Further prospective and clinical intervention studies in large number of subjects are necessary to deÞ nitively prove this hypothesis.
insulin concentrations have been reported in mice with a mutant IGF-I allele causing a marked decrease in circulating IGF-I levels. [20] The present investigation was limited by the fact that the analyses were based on total IGF-I rather than the biologically active free IGF-I. Moreover, the analyses of total IGF-I is very high, it is also possible that the nutritional and genetic factors inß uence the actual levels of circulating IGF-I. In this regard, a polymorphism in the promoter region of the IGF-I gene was associated with low levels of IGF-I and increased risk of type-2 diabetes mellitus. [21] In addition to this, IGF-I binding proteins (IGFBPs) were not measured, which play an important role in regulating the bioavailability of IGF-I. Among IGFBPs, IGFBP-3 is very important since it binds more than 95% of IGF-I in blood circulation. [22] IGF-I has hypoglycemic effects and enhances insulin sensitivity in both experimental and human subjects, which is due to its type-1 receptors and/or hybrid insulin/IGF-I receptors. [23] However, it is not clear how low IGF-I levels may induce insulin insensitivity. The insulin receptors are widely distributed in human tissues [24] and behave as IGF-I homoreceptor rather than insulin homoreceptor or some intermediate of the two receptors. [25] It has been proposed that the hybrid insulin/ IGF-I receptors would reduce insulin sensitivity in target tissues of insulin action leading to insulin resistance. Because of this fact, in patients with insulinoma, a condition characterized by marked hyperinsulinemia, downregulation of insulin receptors induced by elevated plasma insulin was associated with increased abundance of hybrid insulin/IGF-I receptors. [26] Most of the circulating IGF-I is derived from its synthesis in the liver, regulated by growth hormone (GH), insulin, and nutritional intake. [27] Low levels of circulating IGF-I may be because of inadequate negative feedback at the level of the hypothalamus and/or pituitary; thus, resulting in GH hypersecretion and a decrease in insulin sensitivity. In support of this possibility, it has been shown that mice with liver speciÞ c deletion of the IGF-I gene exhibited elevated GH levels, which were associated with insulin resistance and impaired activation of early signaling events in response to insulin. [3] It has been demonstrated that blocking of GH action in mice with liver speciÞ c deletion of the IGF-I gene by crossing them with mice over-expressing a mutant form of GH, which prevents GH activation of its receptor, results in improved insulin sensitivity. Considering these results
